Lamotrigine (All indications) updated on 04-22-2025

Ventricular septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19314
R81793		 Kim (Lamotrigine) (Indications NOS), 2026 Ventricular septal defect 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.39 [0.12;1.31] 3/718   20,989/2,489,078 20,992 718
ref
S10035
R36150		 Blotière (Lamotrigine) (Mixed indications), 2019 Ventricular septal defect 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.30 [0.70;2.50] 10/2,997   4,643/1,875,733 4,653 2,997
ref
Total 2 studies 0.80 [0.25;2.54] 25,645 3,715
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kim (Lamotrigine) (Indications NOS), 2026Kim, 2026 1 0.39[0.12; 1.31]20,99271841%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Blotière (Lamotrigine) (Mixed indications), 2019Blotière, 2019 2 1.30[0.70; 2.50]4,6532,99759%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 67% 0.80[0.25; 2.54]25,6453,7150.25.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Indications NOS; 2: Lamotrigine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.80[0.25; 2.54]25,6453,71567%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.80[0.25; 2.54]25,6453,71567%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 2 Tags Adjustment   - Yes  - Yes 0.80[0.25; 2.54]25,6453,71567%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 2 All studiesAll studies 0.80[0.25; 2.54]25,6453,71567%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 20.15.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.80[0.25; 2.54]25,6453,71567%NAKim (Lamotrigine) (Indications NOS), 2026 Blotière (Lamotrigine) (Mixed indications), 2019 20.510.01.0